Paper41328344
Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy.
Li Y and 14 others. Theranostics, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy. Papers, record 41328344. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41328344
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Endocytosis | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Membrane Proteins | Major topic |
| Clathrin | Major topic |
| Immunotherapy, Adoptive | Major topic |
| T-Lymphocytes | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Cell Line, Tumor | |
| Proteolysis | |
| CTLA-4 Antigen | |
| Xenograft Model Antitumor Assays | |
| Female |
Source PubMed
References72
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33824268 | CAR-T cell therapy: current limitations and potential strategies. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/33824268 | PubMed |
| 2 | 26369987 | Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. | Leukemia | 2016 | https://conductscience.org/library/papers/26369987 | PubMed |
| 3 | 34266984 | A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. | Cancer Discov | 2021 | https://conductscience.org/library/papers/34266984 | PubMed |
| 4 | 11994459 | Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. | J Immunol | 2002 | https://conductscience.org/library/papers/11994459 | PubMed |
| 5 | 22262842 | Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation. | J Biol Chem | 2012 | https://conductscience.org/library/papers/22262842 | PubMed |
| 6 | 37236024 | Regulation of protein prenylation. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/37236024 | PubMed |
| 7 | 38307031 | Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/38307031 | PubMed |
| 8 | 36108050 | Robust deep learning-based protein sequence design using ProteinMPNN. | Science | 2022 | https://conductscience.org/library/papers/36108050 | PubMed |
| 9 | 28622514 | Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. | Cell | 2017 | https://conductscience.org/library/papers/28622514 | PubMed |
| 10 | 29768164 | Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. | Immunity | 2018 | https://conductscience.org/library/papers/29768164 | PubMed |
| 11 | 25939063 | 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. | Nat Med | 2015 | https://conductscience.org/library/papers/25939063 | PubMed |
| 12 | 37433327 | De novo design of protein structure and function with RFdiffusion. | Nature | 2023 | https://conductscience.org/library/papers/37433327 | PubMed |
| 13 | 36814099 | Genetically Programmable Vesicles for Enhancing CAR-T Therapy against Solid Tumors. | Adv Mater | 2023 | https://conductscience.org/library/papers/36814099 | PubMed |
| 14 | 31830245 | Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. | Blood | 2020 | https://conductscience.org/library/papers/31830245 | PubMed |
| 15 | 21779028 | Molecular mechanism and physiological functions of clathrin-mediated endocytosis. | Nat Rev Mol Cell Biol | 2011 | https://conductscience.org/library/papers/21779028 | PubMed |
| 16 | 30684591 | CRISPR-Cas9 for cancer therapy: Opportunities and challenges. | Cancer Lett | 2019 | https://conductscience.org/library/papers/30684591 | PubMed |
| 17 | 36835603 | 4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36835603 | PubMed |
| 18 | 36240777 | Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. | Cancer Cell | 2022 | https://conductscience.org/library/papers/36240777 | PubMed |
| 19 | 32870222 | Nucleic acid constructs for the interrogation of multivalent protein interactions. | Chem Soc Rev | 2020 | https://conductscience.org/library/papers/32870222 | PubMed |
| 20 | 23671122 | Transformation of polarized epithelial cells by apical mistrafficking of epiregulin. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/23671122 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42514964 | Mapping Scientific Landscapes and Therapeutic Innovations of Targeted Protein Degradation: A Scientometric Review. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42514964 | PubMed |
| 42140958 | Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/42140958 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| NR1I3 | 9970 | PubTator's text mining | https://conductscience.org/library/genes/9970 | NCBI Gene |
| TFAP2A | 7020 | PubTator's text mining | https://conductscience.org/library/genes/7020 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41328344
GET https://conductscience.org/api/papers/v1/41328344/references?page=2